Pinnacle Associates’s Myriad Genetics MYGN Stock Holding History

Pinnacle Associates’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$43.7K	Buy	+10,145	New	+$42.8K	﹤0.01%	951
2020 Q4	–	Sell	-10,678	Closed	-$139K	–	713
2020 Q3	$139K	Sell	10,678 -294,505	-97%	-$3.73M	﹤0.01%	656
2020 Q2	$3.46M	Sell	305,183 -11,745	-4%	-$167K	0.09%	215
2020 Q1	$4.54M	Sell	316,928 -64,673	-17%	-$1.37M	0.14%	165
2019 Q4	$10.4M	Sell	381,601 -30,980	-8%	-$852K	0.23%	122
2019 Q3	$11.8M	Sell	412,581 -28,157	-6%	-$820K	0.28%	100
2019 Q2	$12.2M	Sell	440,738 -39,099	-8%	-$1.1M	0.29%	95
2019 Q1	$15.9M	Buy	479,837 +7,200	+2%	+$219K	0.36%	78
2018 Q4	$13.7M	Sell	472,637 -24,694	-5%	-$888K	0.35%	80
2018 Q3	$22.9M	Sell	497,331 -79,442	-14%	-$3.53M	0.47%	60
2018 Q2	$21.6M	Sell	576,773 -102,270	-15%	-$3.45M	0.44%	63
2018 Q1	$20.1M	Sell	679,043 -32,444	-5%	-$1.1M	0.39%	73
2017 Q4	$24.4M	Sell	711,487 -67,794	-9%	-$2.29M	0.47%	62
2017 Q3	$28.2M	Sell	779,281 -21,650	-3%	-$618K	0.52%	58
2017 Q2	$20.7M	Sell	800,931 -33,025	-4%	-$701K	0.4%	73
2017 Q1	$16M	Sell	833,956 -37,077	-4%	-$657K	0.31%	92
2016 Q4	$14.5M	Sell	871,033 -51,703	-6%	-$935K	0.29%	97
2016 Q3	$19M	Sell	922,736 -13,440	-1%	-$341K	0.38%	80
2016 Q2	$28.6M	Sell	936,176 -13,443	-1%	-$467K	0.62%	41
2016 Q1	$35.5M	Buy	949,619 +5,110	+0.5%	+$193K	0.76%	33
2015 Q4	$40.8M	Sell	944,509 -58,351	-6%	-$2.47M	0.86%	29
2015 Q3	$37.6M	Sell	1,002,860 -28,800	-3%	-$1.02M	0.83%	30
2015 Q2	$35.1M	Sell	1,031,660 -30,770	-3%	-$1.05M	0.65%	38
2015 Q1	$37.6M	Sell	1,062,430 -4,121	-0.4%	-$147K	0.7%	32
2014 Q4	$36.3M	Buy	1,066,551 +52,405	+5%	+$1.86M	0.71%	33
2014 Q3	$39.1M	Sell	1,014,146 -42,474	-4%	-$1.58M	0.8%	28
2014 Q2	$41.1M	Sell	1,056,620 -66,467	-6%	-$2.47M	0.8%	32
2014 Q1	$38.4M	Sell	1,123,087 -49,840	-4%	-$1.54M	0.75%	36
2013 Q4	$24.6M	Sell	1,172,927 -29,900	-2%	-$756K	0.48%	58
2013 Q3	$28.3M	Sell	1,202,827 -66,029	-5%	-$1.88M	0.58%	41
2013 Q2	$34.1M	Buy	+1,268,856	New	+$36.8M	0.77%	34

Other funds holding MYGN

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Harbor Capital Advisors Chicago, Illinois $1.48B AUM 30.88% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Williams & Novak Westlake Village, California $169M AUM 17.63% 1-Year Est. Return

State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

SignatureFD Atlanta, Georgia $7.76B AUM 16.09% 1-Year Est. Return

Physician Wealth Advisors Midvale, Utah $869M AUM 17.6% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

Pinnacle Associates's MYGN Position: Q3 2026 in Review

Pinnacle Associates opened a new position in Myriad Genetics (MYGN) in Q3 2026: 10,145 shares worth $43.7K. The stake represents ﹤0.01% of the portfolio and ranks #951 among its holdings. This is a return to the name: Pinnacle Associates previously reported a position in MYGN as recently as Q3 2020.

Pinnacle Associates first reported a position in MYGN in Q2 2013 and has held it in 31 quarters since. The position peaked at $41.1M in Q2 2014. 21 funds tracked by Wall St. Rank hold MYGN as of Q3 2026.

Pinnacle Associates held 10,145 shares of Myriad Genetics worth $43.7K as of Q3 2026.
Myriad Genetics was a new Pinnacle Associates position in Q3 2026.
Myriad Genetics made up ﹤0.01% of Pinnacle Associates's portfolio in Q3 2026, its #951 holding.
Pinnacle Associates first reported a position in Myriad Genetics in Q2 2013 and has held it in 31 quarters since.
Pinnacle Associates's Myriad Genetics position peaked at $41.1M in Q2 2014.
21 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2026.

Based on Pinnacle Associates's 13F filing for Q3 2026, filed 20 Oct 2026.